Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 1
2002 1
2003 1
2004 2
2005 4
2006 5
2007 12
2008 15
2009 9
2010 7
2011 6
2012 8
2013 2
2014 2
2015 4
2016 1
2017 1
2018 3
2019 5
2020 6
2021 11
2022 11
2023 7
2024 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: antonioli e. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Marchioli R, et al. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. N Engl J Med. 2013. PMID: 23216616 Free article. Clinical Trial.
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports.
Attucci I, Pilerci S, Messeri M, Pengue L, Tomasino G, Caroti L, Vannucchi AM, Antonioli E. Attucci I, et al. Among authors: antonioli e. Cancer Rep (Hoboken). 2024 Oct;7(10):e2163. doi: 10.1002/cnr2.2163. Cancer Rep (Hoboken). 2024. PMID: 39390755 Free PMC article. Review. Spanish.
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Brodsky RA, et al. Among authors: antonioli e. Blood. 2008 Feb 15;111(4):1840-7. doi: 10.1182/blood-2007-06-094136. Epub 2007 Nov 30. Blood. 2008. PMID: 18055865 Free article. Clinical Trial.
Chemotherapy-related nail toxicity.
Antonioli E, Fani A, Sordi B, Puccini B, Bosi A. Antonioli E, et al. Int J Hematol. 2019 Nov;110(5):519-520. doi: 10.1007/s12185-019-02724-9. Epub 2019 Aug 10. Int J Hematol. 2019. PMID: 31401768 No abstract available.
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study.
Attardi E, Pilerci S, Attucci I, Buzzichelli A, Messeri M, Staderini M, Vannucchi AM, Antonioli E. Attardi E, et al. Among authors: antonioli e. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):e850-e852. doi: 10.1016/j.clml.2021.06.018. Epub 2021 Jun 28. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34344639 No abstract available.
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, van de Donk NWCJ, Katodritou E, Schjesvold F, Balari AS, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P. Sonneveld P, et al. Among authors: antonioli e. Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17. Future Oncol. 2024. PMID: 39287147
121 results